Author:
Li Hui-dan,Chen Si-si,Ding Jing,Zhang Chun-ling,Qiu Hui-yin,Xia Xin-xin,Yang Jun,Wang Xiao-rui
Funder
National Natural Science Foundation of China
Clinical Research Innovation Plan of Shanghai General Hospital
Shanghai Hospital Development Center
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG et al (2016) Characterization of leukemias with ETV6-ABL1 fusion. Haematologica 101(9):1082–1093 (PMID: 27229714)
2. Kakadia PM, Schmidmaier R, Völkl A, Schneider I, Huk N, Schneider S et al (2016) An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: initial response to Imatinib followed by rapid transformation into ALL. Leuk Res Rep 6:50–54 (PMID: 27812500)
3. Song JS, Shin SY, Lee ST, Kim HJ, Kim SH (2014) A cryptic ETV6/ABL1 rearrangement represents a unique fluorescence in situ hybridization signal pattern in a patient with B acute lymphoblastic leukemia. Ann Lab Med 34(6):475–477 (PMID: 25368826)
4. Tirado CA, Siangchin K, Shabsovich DS, Sharifian M, Schiller G (2016) A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature. Biomark Res 4(1):16 (PMID: 27570624)
5. Tirado CA, Sebastian S, Moore JO, Gong JZ, Goodman BK (2005) Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet Cytogenet 157(1):74–77 (PMID: 15676152)